




CLERK, U.S. BANKRUPTCY COURT  
NORTHERN DISTRICT OF TEXAS

**ENTERED**

THE DATE OF ENTRY IS ON  
THE COURT'S DOCKET

The following constitutes the ruling of the court and has the force and effect therein described.

Signed May 28, 2025

  
United States Bankruptcy Judge

**IN THE UNITED STATES BANKRUPTCY COURT  
FOR THE NORTHERN DISTRICT OF TEXAS  
DALLAS DIVISION**

In re:

EIGER BIOPHARMACEUTICALS, INC.,  
*et al.*<sup>1</sup>

Debtors.

Chapter 11

Case No. 24-80040 (SGJ)

(Jointly Administered)

**ORDER DENYING LIQUIDATING TRUSTEE'S MOTION FOR SUMMARY  
JUDGMENT ON CONTESTED MATTER, EXPUNGING ADMINISTRATIVE CLAIM  
OF SENTYNL THERAPEUTICS, INC.**

Came on for consideration the motion filed on April 21, 2025 at Docket No. 832 (the "Motion")<sup>2</sup> by Dundon Advisers LLC, c/o Joshua Nahas, in its capacity as liquidating trustee (the "Liquidating Trustee" or "LT") of the liquidating trust of Eiger BioPharmaceuticals, Inc., et al.

<sup>1</sup> The Debtors in these chapter 11 cases, together with the last four digits of each Debtor's federal tax identification number, are: Eiger BioPharmaceuticals, Inc. (1591); EBPI Merger Inc. (9986); EB Pharma LLC (8352); Eiger BioPharmaceuticals Europe Limited (N/A); and EigerBio Europe Limited (N/A). The Debtors' service address is 2100 Ross Avenue, Dallas, Texas 75201.

<sup>2</sup> Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to them in the Motion.



248004025052800000000001

(the “Debtor” or “Eiger” or “Eiger Bio”) for Summary Judgment On Contested Matter, Expunging Administrative Claim of Sentynl Therapeutics, Inc. (“Sentynl”). Upon consideration of the Motion, the response filed by Sentynl, the evidence presented, and the arguments of counsel this Court finds, for the reasons stated in the record, that the Motion should be denied. It is, therefore:

ORDERED that the Motion is denied.

**### END OF ORDER ###**